Jump Financial LLC Purchases Shares of 46,120 Merus (NASDAQ:MRUS)

Jump Financial LLC bought a new stake in shares of Merus (NASDAQ:MRUS - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 46,120 shares of the biotechnology company's stock, valued at approximately $1,268,000. Jump Financial LLC owned about 0.08% of Merus as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of MRUS. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lifted its holdings in Merus by 10.8% during the third quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 13,446 shares of the biotechnology company's stock worth $317,000 after acquiring an additional 1,310 shares during the period. Exchange Traded Concepts LLC lifted its holdings in Merus by 34.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 5,753 shares of the biotechnology company's stock worth $158,000 after acquiring an additional 1,459 shares during the period. Corton Capital Inc. lifted its holdings in Merus by 33.6% during the third quarter. Corton Capital Inc. now owns 12,420 shares of the biotechnology company's stock worth $293,000 after acquiring an additional 3,127 shares during the period. Arizona State Retirement System lifted its holdings in Merus by 43.1% during the third quarter. Arizona State Retirement System now owns 12,103 shares of the biotechnology company's stock worth $285,000 after acquiring an additional 3,647 shares during the period. Finally, Teacher Retirement System of Texas lifted its holdings in Merus by 47.9% during the third quarter. Teacher Retirement System of Texas now owns 12,084 shares of the biotechnology company's stock worth $285,000 after acquiring an additional 3,916 shares during the period. Hedge funds and other institutional investors own 96.14% of the company's stock.

Merus Trading Down 2.5 %

Shares of NASDAQ MRUS traded down $1.11 during mid-day trading on Friday, hitting $43.91. The company had a trading volume of 486,819 shares, compared to its average volume of 609,955. The company has a market capitalization of $2.58 billion, a price-to-earnings ratio of -16.25 and a beta of 1.10. Merus has a 1 year low of $19.81 and a 1 year high of $52.03. The stock's 50-day moving average price is $44.52 and its 200-day moving average price is $36.27.

Merus (NASDAQ:MRUS - Get Free Report) last announced its quarterly earnings results on Wednesday, May 8th. The biotechnology company reported ($0.59) earnings per share for the quarter, beating the consensus estimate of ($0.83) by $0.24. The company had revenue of $7.89 million during the quarter, compared to analysts' expectations of $8.94 million. Merus had a negative return on equity of 44.13% and a negative net margin of 390.36%. As a group, equities research analysts forecast that Merus will post -3.14 earnings per share for the current year.

Wall Street Analyst Weigh In

MRUS has been the topic of several research reports. Truist Financial initiated coverage on Merus in a research note on Thursday, March 28th. They issued a "buy" rating and a $69.00 target price on the stock. BMO Capital Markets boosted their target price on Merus from $49.00 to $58.00 and gave the company an "outperform" rating in a research note on Thursday, February 29th. Needham & Company LLC restated a "buy" rating and issued a $66.00 target price on shares of Merus in a research note on Monday. Stifel Nicolaus boosted their target price on Merus from $40.00 to $65.00 and gave the company a "buy" rating in a research note on Thursday, February 29th. Finally, William Blair restated an "outperform" rating on shares of Merus in a research note on Monday, April 22nd. One research analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $56.33.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.